Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEMAFOOT2 Pilot
2023-504913-65-01Phase 2Authorised
- Sponsor
- Bispebjerg and Frederiksberg Hospital
- Start
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of semaglutide in type 2 diabetes mellitus (T2DM) and diabetic foot ulcer (DFU) (2 arms), sponsored by Bispebjerg and Frederiksberg Hospital. Primary endpoint: Proportion of index ulcers completely healed after 20 weeks of intervention. Planned start Jun 2025; status: authorised.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on 2023-504913-65-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504913-65-01.